Elevated Endogenous Insulin and Insulin Resistance in Progressive Diastolic Dysfunction and Cardiovascular Risk: A Comprehensive Clinical Review

MedXY Editorial Team•Aug 11, 2026•Cardiology

Elevated endogenous insulin and insulin resistance independently predict progressive diastolic dysfunction (DD) over four years, preceding overt diabetes onset.
Insulin dysregulation associates with increased long-term all-cause and cardiovascular mortality, even after adjusting for body mass index and other confounders.
Metabolic perturbations may initiate myocardial stiffening and impaired relaxation in early preclinical stages, offering a potentially actionable window to prevent heart failure with preserved ejection fraction (HFpEF).
Findings suggest integration of insulin resistance assessment in cardiovascular risk stratification and highlight the need for therapeutic strategies targeting metabolic abnormalities to halt DD progression.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Elevated endogenous insulin and insulin resistance independently predict progressive diastolic dysfunction (DD) over four years, preceding overt diabetes onset.
Insulin dysregulation associates with increased long-term all-cause and cardiovascular mortality, even after adjusting for body mass index and other confounders.
Metabolic perturbations may initiate myocardial stiffening and impaired relaxation in early preclinical stages, offering a potentially actionable window to prevent heart failure with preserved ejection fraction (HFpEF).
Findings suggest integration of insulin resistance assessment in cardiovascular risk stratification and highlight the need for therapeutic strategies targeting metabolic abnormalities to halt DD progression.